Stocks higher after FDA grant full approval of Pfizer BioNTech vaccine

Stocks higher after FDA grant full approval of Pfizer BioNTech vaccine

Share on facebook
Share on twitter
Share on linkedin

Stocks are advancing again this morning, following Asian markets higher, after the US FDA granted full approval of the Pfizer/BioNTech vaccine for COVID-19. Sentiment has also been lifted by Dallas Fed President Robert Kaplan who said on Friday he would reconsider his views on a taper if data showed the current Covid surge was causing the economy to slow.

Concerns that the Fed would soon begin tapering prompted the recent sell-off but those fears abated a little after data showed US private sector growth slowed in August to an 8-month low.

Focus is now on the Jackson Hole Symposium later in the week and particularly Jerome Powell’s speech on Friday where he is expected to indicate the timing of the central bank’s reduction in the bond-buying program.

 

Disclaimer:  ‘Where the business has expressed opinions, they are based on current market conditions, they may differ from those of other investment professionals and are subject to change without notice. The information contained within this communication is believed to be reliable but Realm Investment Management Limited does not warrant its completeness or accuracy. This communication is not intended as a recommendation to invest in any particular asset class, security or strategy. Regulatory requirements that require impartiality of investment/investment strategy recommendations are therefore not applicable nor are any prohibitions to trade before publication. The information provided is for illustrative purposes only, it should not be relied upon as recommendations to buy or sell investments.’

Download Our Free Brochure